A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...
Charlotte Patterson previews today’s Wear derby between Sunderland and Durham. Who’ll claim the bragging rights?
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates ...
Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta ...
Nigel Jones tackles the everlasting question of workforce planning in light of recent developments in the dental sector.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ...
Researchers at The Institute of Cancer Research, London identified the CIP2A–TOPBP1 complex as a master regulator of DNA ...
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of im ...
Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...
CSA Medical, Inc., a medical device company focused on interventional pulmonary therapies, today announced the submission of ...
No. The press release never says that Citrus Burn enhances metabolism, leads to weight loss, and produces certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback